News Sentiment

ADCT sentiment intelligence

ADC Therapeutics SA news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 58 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.29 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+8.4% over one week, +22.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 8.4% Price confirming higher
Trend fit Trend inactive 22.9% over four weeks
Fair value -53.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 35
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 8
PR Newswire 7
TradingView 6
ACCESS Newswire 4
MT Newswires 3
simplywall.st 3
grafa.com 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 17
Regulatory and legal 6
Balance sheet 3
Analyst action 2
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (ADCT) following a significant drop in its stock price. This investigation comes after the announcement of top-line data from ADC's Phase 3 LOTIS-5 trial, which, despite extending pro

Tone
Negative 19/100
Event
Regulatory and legal
Published
19 Jun 2026 11:00
Source
ACCESS Newswire
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (ADCT) on behalf of investors. This investigation follows a significant drop in ADC's stock price after the company released topline data from its Phase 3 LOTIS-5 trial for ZYNLONTA®, whi

Tone
Negative 8/100
Event
Regulatory and legal
Published
18 Jun 2026 13:59
Source
PR Newswire
TradingKey Direct company coverage

ADC Therapeutics SA (ADCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for ADC Therapeutics SA (ADCT), detailing its business segments. It shows that Product sales account for 90.41% of revenue, followed by License revenue at 6.15%, and Royalties at 3.45%. The article also notes that relevant regional data f

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:40
Source
TradingKey
ACCESS Newswire Direct company coverage

ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (NYSE:ADCT) following a significant stock price drop. This drop occurred after the company announced Phase 3 trial data for ZYNLONTA®, which, despite extending progression-free surviv

Tone
Negative 20/100
Event
Regulatory and legal
Published
17 Jun 2026 20:39
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) securities. This investigation follows the announcement of topline data from ADC's Phase 3 LOTIS-5 trial, where ZYNLONTA® extended progression-free survival

Tone
Negative 9/100
Event
Regulatory and legal
Published
15 Jun 2026 16:40
Source
ACCESS Newswire